Literature DB >> 23467926

Preoperative carcinoembryonic antigen level predicts prognosis in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Emel Canbay1, Haruaki Ishibashi, Shouzou Sako, Akiyoshi Mizumoto, Masamitsu Hirano, Masumi Ichinose, Nobuyuki Takao, Yutaka Yonemura.   

Abstract

BACKGROUND: Even though management of pseudomyxoma peritonei (PMP) was improved with cytoreductive surgery (CRS) and hyperthermic chemotherapy (HIPEC), several aspects of PMP still need to be optimized, including patient selection for surgery and prognostic factors. We assessed the role of preoperative carcinoembryonic antigen (CEA) levels in PMP patients treated with CRS and HIPEC.
METHODS: A total of 449 PMP patients with documented preoperative CEA levels referred to our center between 2005 and 2011 underwent CRS and HIPEC. The association between CEA levels and characteristics of patients with PMP was assessed with χ (2) test, linear correlation, and logistic regression analyses. Survival analysis was performed with Cox proportional hazard model.
RESULTS: Median age was 55 (range 19-84) years. There were 245 (54.5 %) females and 204 (45.5 %) males. Preoperative CEA levels were elevated in 328 (73 %, sensitivity) patients with PMP. Preoperative CEA levels were also related to peritoneal cancer index (P < 0.0001), cytoreductive surgery scores (P < 0.0001), progress free survival (P < 0.001) and overall survival (P < 0.001) in patients with PMP.
CONCLUSIONS: Our results indicated that preoperative CEA levels are useful in predicting the extent of disease and surgical success as well as progress-free and overall survival in patients with PMP treated with cytoreductive surgery and HIPEC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23467926     DOI: 10.1007/s00268-013-1988-7

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  16 in total

1.  Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy.

Authors:  P H Sugarbaker; D Chang
Journal:  Ann Surg Oncol       Date:  1999-12       Impact factor: 5.344

2.  Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Authors:  Terence C Chua; Brendan J Moran; Paul H Sugarbaker; Edward A Levine; Olivier Glehen; François N Gilly; Dario Baratti; Marcello Deraco; Dominique Elias; Armando Sardi; Winston Liauw; Tristan D Yan; Pedro Barrios; Alberto Gómez Portilla; Ignace H J T de Hingh; Wim P Ceelen; Joerg O Pelz; Pompiliu Piso; Santiago González-Moreno; Kurt Van Der Speeten; David L Morris
Journal:  J Clin Oncol       Date:  2012-05-21       Impact factor: 44.544

3.  Elevated tumour markers prior to complete tumour removal in patients with pseudomyxoma peritonei predict early recurrence.

Authors:  F Alexander-Sefre; K Chandrakumaran; S Banerjee; R Sexton; J M Thomas; B Moran
Journal:  Colorectal Dis       Date:  2005-07       Impact factor: 3.788

4.  Early recurrence of pseudomyxoma peritonei following treatment failure of cytoreductive surgery and perioperative intraperitoneal chemotherapy is indicative of a poor survival outcome.

Authors:  Terence C Chua; Winston Liauw; David L Morris
Journal:  Int J Colorectal Dis       Date:  2011-08-19       Impact factor: 2.571

5.  Clinical utility of elevated tumor markers in patients with disseminated appendiceal malignancies treated by cytoreductive surgery and HIPEC.

Authors:  A Ross; A Sardi; C Nieroda; B Merriman; V Gushchin
Journal:  Eur J Surg Oncol       Date:  2010-06-18       Impact factor: 4.424

Review 6.  The etiology, clinical presentation, and management of pseudomyxoma peritonei.

Authors:  Brendan J Moran; Thomas D Cecil
Journal:  Surg Oncol Clin N Am       Date:  2003-07       Impact factor: 3.495

7.  Appendiceal mucinous neoplasms: a clinicopathologic analysis of 107 cases.

Authors:  Joseph Misdraji; Rhonda K Yantiss; Fiona M Graeme-Cook; Ulysses J Balis; Robert H Young
Journal:  Am J Surg Pathol       Date:  2003-08       Impact factor: 6.394

8.  Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to "pseudomyxoma peritonei".

Authors:  B M Ronnett; C M Zahn; R J Kurman; M E Kass; P H Sugarbaker; B M Shmookler
Journal:  Am J Surg Pathol       Date:  1995-12       Impact factor: 6.394

9.  Peritonectomy procedures.

Authors:  P H Sugarbaker
Journal:  Ann Surg       Date:  1995-01       Impact factor: 12.969

10.  Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer.

Authors:  Rhonda L Harmon; Paul H Sugarbaker
Journal:  Int Semin Surg Oncol       Date:  2005-02-08
View more
  7 in total

1.  The Utility of Preoperative Tumor Markers in Peritoneal Carcinomatosis from Primary Appendiceal Adenocarcinoma: an Analysis from the US HIPEC Collaborative.

Authors:  Nadege Fackche; Ryan K Schmocker; Boateng Kubi; Jordan M Cloyd; Ahmed Ahmed; Travis Grotz; Jennifer Leiting; Keith Fournier; Andrew J Lee; Benjamin Powers; Sean Dineen; Jula Veerapong; Joel M Baumgartner; Callisia Clarke; T Clark Gamblin; Sameer H Patel; Vikrom Dhar; Ryan J Hendrix; Laura Lambert; Daniel E Abbott; Courtney Pokrzywa; Kelly Lafaro; Byrne Lee; Mohammad Y Zaidi; Shishir K Maithel; Fabian M Johnston; Jonathan B Greer
Journal:  J Gastrointest Surg       Date:  2021-02-25       Impact factor: 3.452

Review 2.  Evolution of management in peritoneal surface malignancies.

Authors:  Emel Canbay; Bahar Canbay Torun; Ege Sinan Torun; Yutaka Yonemura
Journal:  Ulus Cerrahi Derg       Date:  2015-09-01

3.  Controversy and consensus on the management of patients with pseudomyxoma peritonei.

Authors:  Jason E Faris; David P Ryan
Journal:  Curr Treat Options Oncol       Date:  2013-09

4.  Risk factors for esophageal fistula in patients with locally advanced esophageal carcinoma receiving chemoradiotherapy.

Authors:  Yang Zhang; Zongjuan Li; Wei Zhang; Wei Chen; Yipeng Song
Journal:  Onco Targets Ther       Date:  2018-04-23       Impact factor: 4.147

5.  Pseudomyxoma Peritonei Originating from Transverse Colon Mucinous Adenocarcinoma: A Case Report and Literature Review.

Authors:  Yingbo Gong; Xin Wang; Zhi Zhu
Journal:  Gastroenterol Res Pract       Date:  2020-07-03       Impact factor: 2.260

6.  Factors influencing long-term survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei originating from appendiceal neoplasms.

Authors:  W J van Eden; N F M Kok; P Snaebjornsson; K Jóźwiak; K Woensdregt; P D Bottenberg; H Boot; A G J Aalbers
Journal:  BJS Open       Date:  2019-02-19

7.  Aggressive pseudomyxoma peritonei: a case report with an unusual clinical presentation.

Authors:  Zisis Touloumis; George Galyfos; Nikolaos Kavouras; Michalis Menis; Laurant Lavant
Journal:  Case Rep Oncol Med       Date:  2013-11-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.